Ignite Creation Date:
2025-12-25 @ 3:45 AM
Ignite Modification Date:
2025-12-26 @ 2:32 AM
Study NCT ID:
NCT05754502
Status:
UNKNOWN
Last Update Posted:
2023-03-03
First Post:
2023-02-21
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Observational Study of Effectiveness and Safety of Trastuzumab Emtansine (T-DM1) in HER2-positive Breast Cancer Patients With Residual Invasive Disease Following Neoadjuvant Chemotherapy and Anti-HER2 Target Therapy
Sponsor:
Consorzio Oncotech
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2021-07-27
Start Date Type:
ACTUAL
Primary Completion Date:
2024-09-21
Primary Completion Date Type:
ESTIMATED
Completion Date:
2025-05-02
Completion Date Type:
ESTIMATED
First Submit Date:
2023-02-21
First Submit QC Date:
None
Study First Post Date:
2023-03-03
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2023-03-02
Last Update Post Date:
2023-03-03
Last Update Post Date Type:
ACTUAL